Sanchez I, De Koster J, Powell R E, Wolstein R, Chernick V
Department of Pediatrics, University of Manitoba, Winnipeg, Canada.
J Pediatr. 1993 Jan;122(1):145-51. doi: 10.1016/s0022-3476(05)83508-5.
To test the efficacy of a combined alpha- and beta-receptor agonist in acute bronchiolitis, we compared inhaled racemic epinephrine with salbutamol in a double-blind, crossover, randomized protocol. Twenty-four infants, 4.6 +/- 0.5 (mean +/- SEM) months of age, with their first episode of bronchiolitis were tested. After sedation with chloral hydrate, a clinical score and pulmonary mechanics measurements using simultaneous signals of airflow volume and transpulmonary pressure were recorded. After baseline measurements, infants received either nebulized salbutamol, 0.03 ml/kg, or racemic epinephrine, 0.1 ml/kg. Thirty minutes later, there was a significant decrease in clinical score after treatment with racemic epinephrine compared with the baseline score (p < 0.001); this difference was not present after salbutamol inhalation (p = 0.42). Only 13 patients had a decrease in clinical score after salbutamol therapy, in comparison with 20 infants treated with racemic epinephrine (p < 0.01). Both drug decreased respiratory rate, but the decrease was greater after the use of racemic epinephrine (p < 0.001). There was a significant decrease in inspiratory, expiratory, and total pulmonary resistance after treatment with racemic epinephrine compared with baseline values (p < 0.01) but no significant change after salbutamol inhalation. There was no significant correlation between the clinical score and pulmonary mechanics either at baseline or after drug treatment. We conclude that racemic epinephrine is superior to salbutamol in the treatment of infants with their first episode of acute bronchiolitis.
为了测试α和β受体联合激动剂在急性细支气管炎中的疗效,我们采用双盲、交叉、随机方案,将吸入消旋肾上腺素与沙丁胺醇进行了比较。对24例首次患细支气管炎、年龄为4.6±0.5(均值±标准误)个月的婴儿进行了测试。在用水合氯醛镇静后,记录临床评分以及使用气流容积和跨肺压同步信号进行的肺力学测量结果。在进行基线测量后,婴儿接受雾化沙丁胺醇(0.03 ml/kg)或消旋肾上腺素(0.1 ml/kg)治疗。30分钟后,与基线评分相比,消旋肾上腺素治疗后临床评分显著降低(p<0.001);吸入沙丁胺醇后未出现这种差异(p = 0.42)。与20例接受消旋肾上腺素治疗的婴儿相比,沙丁胺醇治疗后只有13例患者临床评分降低(p<0.01)。两种药物均降低了呼吸频率,但使用消旋肾上腺素后降低幅度更大(p<0.001)。与基线值相比,消旋肾上腺素治疗后吸气、呼气和总肺阻力显著降低(p<0.01),但吸入沙丁胺醇后无显著变化。在基线时或药物治疗后,临床评分与肺力学之间均无显著相关性。我们得出结论,在治疗首次患急性细支气管炎的婴儿时,消旋肾上腺素优于沙丁胺醇。